ReviewCancers2021
Current Treatment Options in CLL.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- TLR8 Stimulation Leads to Microenvironment Activation and Enhanced Antibody-Dependent Cellular Responses in CLL.International journal of molecular sciences · 2026Article
- Article
- Real-world clinical outcomes in patients with CLL previously treated with covalent BTKi and BCL2i regimens.Blood neoplasia · 2026Article
- Epidemiology of chronic lymphocytic leukaemia in Germany: A retrospective analysis of administrative claims data.Annals of hematology · 2025Observational
- Overall Survival Associated with Real-World Treatment Sequences in Patients with CLL/SLL in the United States.Cancers · 2025Article
- Leveraging diverse cell-death patterns to predict to predict prognosis and immunotherapy in hepatocellular carcinoma.Discover oncology · 2025Article
- Article
- Extranodal Manifestation of Chronic Lymphocytic Leukemia: A Case of Bilateral Breast Involvement.Clinical case reports · 2025Article
- Real-World Effectiveness of Frontline Treatments Among Patients with Chronic Lymphocytic Leukemia: Results from ConcertAI.Cancers · 2025Article
- Raman spectroscopy and bioinformatics-based identification of key genes and pathways capable of distinguishing between diffuse large B cell lymphoma and chronic lymphocytic leukemia.Frontiers in immunology · 2025Article
- Upfront fixed-duration treatment strategies for chronic lymphocytic leukemia in Arab populations: a position statement from the Gulf region.Frontiers in medicine · 2025Article
- Predicting progression-free survival from measurable residual disease in chronic lymphocytic leukemia.Clinical and translational science · 2024Article
- Article
- Article
- Patient preferences for chronic lymphocytic leukemia treatments: a discrete-choice experiment.Future oncology (London, England) · 2024Article
- The role of polymorphic cytochrome P450 gene (CYP2B6) in B-chronic lymphocytic leukemia (B-CLL) incidence and outcome among Egyptian patients.Oncology research · 2024Article
- Expert consensus on the management of chronic lymphocytic leukaemia in Asia.Clinical and experimental medicine · 2023Article
- Article
- Treatment patterns in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma post covalent Bruton tyrosine kinase inhibitor treatment: a Japanese claims database study.Journal of clinical and experimental hematopathology : JCEH · 2023Article
- Membranous nephropathy in chronic lymphocytic leukemia responsive to ibrutinib: A case report.Leukemia research reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
After impressive developments in recent years with the rise of new targeted agents, chemoimmunotherapy (CIT) only plays a minor role in the treatment of patients with chronic lymphocytic leukemia (CLL). Inhibitors of the Bruton tyrosine kinase (BTK), such as ibrutinib or more recently acalabrutinib, are highly effective, even in poor-risk or chemo-refractory patients. Venetoclax, an inhibitor of the anti-apoptotic BCL2 protein and, to a lesser extent, phosphoinositide-3 kinase (PI3K) delta inhibitors, add to the armamentarium of targeted agents for the treatment of CLL. Furthermore, anti-CD20 monoclonal antibodies are used very successfully either alone or in combination with BTK, BCL2 or PI3K inhibitors. Despite these advances, there is still an ongoing pursuit for new therapeutic approaches in the treatment of CLL. An even bigger challenge poses the determination of the optimal combination and sequence of those drugs. Here, we give an overview of current treatment options in CLL, weighing the advantages and disadvantages of each approach in the light of different clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.